Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EBT: 2012-2024

Historic EBT for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to -$165.1 million.

  • Ocular Therapeutix's EBT fell 56.01% to -$68.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$247.3 million, marking a year-over-year decrease of 78.13%. This contributed to the annual value of -$165.1 million for FY2024, which is 83.96% down from last year.
  • Per Ocular Therapeutix's latest filing, its EBT stood at -$165.1 million for FY2024, which was down 83.96% from -$89.7 million recorded in FY2023.
  • In the past 5 years, Ocular Therapeutix's EBT ranged from a high of -$69.4 million in FY2020 and a low of -$165.1 million during FY2024.
  • For the 3-year period, Ocular Therapeutix's EBT averaged around -$113.2 million, with its median value being -$89.7 million (2023).
  • As far as peak fluctuations go, Ocular Therapeutix's EBT grew by 23.41% in 2020, and later plummeted by 83.96% in 2024.
  • Yearly analysis of 5 years shows Ocular Therapeutix's EBT stood at -$69.4 million in 2020, then fell by 21.93% to -$84.7 million in 2021, then dropped by 0.24% to -$84.9 million in 2022, then declined by 5.72% to -$89.7 million in 2023, then plummeted by 83.96% to -$165.1 million in 2024.